PDS Biotechnology Corporation
PDSB
$0.29
-$0.01-2.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.26% | -6.43% | -19.84% | 5.60% | -17.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.78% | -28.39% | -9.32% | -20.03% | -12.22% |
| Operating Income | 14.78% | 28.39% | 9.32% | 20.03% | 12.22% |
| Income Before Tax | -3.35% | 23.91% | 4.90% | 16.01% | -2.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.35% | 13.43% | 4.90% | 16.01% | -13.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.35% | 13.43% | 4.90% | 16.01% | -13.28% |
| EBIT | 14.78% | 28.39% | 9.32% | 20.03% | 12.22% |
| EBITDA | 14.81% | 28.43% | 9.34% | 20.06% | 12.24% |
| EPS Basic | 14.74% | 36.80% | 30.88% | 34.04% | 9.47% |
| Normalized Basic EPS | 14.79% | 44.43% | 30.92% | 34.05% | 18.00% |
| EPS Diluted | 14.74% | 36.80% | 30.88% | 34.04% | 9.47% |
| Normalized Diluted EPS | 14.79% | 44.43% | 30.92% | 34.05% | 18.00% |
| Average Basic Shares Outstanding | 21.26% | 36.96% | 37.62% | 27.34% | 25.10% |
| Average Diluted Shares Outstanding | 21.26% | 36.96% | 37.62% | 27.34% | 25.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |